Polestar (PSNY) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Company Participants Anna Gavrilova - Head of IRMichael Lohscheller - CEOJean-Francois Mady - CFO Conference Call Participants John Babcock - AnalystDaniel Röska - AnalystTobias Beith - Research AnalystAndres Sheppard - AnalystDan Levy - Senior Equity Research Analyst Operator Good day and thank you for standing by. Welcome to the Pulsar Q1 twenty twenty five Results Conference Call. At this time, all participants are in a listen only mode. Afte ...

Kaspi.kz (KSPI) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Company Participants David Ferguson - MD & Head of Investor RelationsMikheil Lomtadze - Chairman of the Management Board , CEO & DirectorYgal Arounian - Director - Internet Equity ResearchDarrin Peller - Managing DirectorReggie Smith - Executive Director - Equity Research Conference Call Participants Jamie Friedman - Senior FinTech and IT Services Research AnalystNone - AnalystGabor Kemeny - Senior Analyst Operator Hello, and welcome, everyone, ...

Kaspi.kz (KSPI) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Speaker0 Hello, and welcome, everyone, to the Kaspi KZ First Quarter twenty twenty five Financial Results. I will now hand you over to David Ferguson, Head of Investor Relations at Cassidy Cape Verde to begin. David, please go ahead. Speaker1 Great. Thank you, Maxine. Good afternoon, good morning to everyone. Thanks a lot for joining us for our first quarter twenty twenty five financial results. I'm David Ferguson. I'm joined, as usual, by Mikha ...

Financial Data and Key Metrics Changes - CytomX Therapeutics announced a financing of $100 million with a leading group of healthcare investors, which underscores the confidence in the company's progress and potential [3][7] - The company reported a 28% confirmed overall response rate and a 94% disease control rate for CX-2051 in metastatic colorectal cancer, with a preliminary progression-free survival of 5.8 months [11][26] Business Line Data and Key Metrics Changes - CX-2051, an antibody-drug conjugate targeting EpCAM, has shown promising results in a Phase I clinical trial focused exclusively on metastatic colorectal cancer [11][19] - The trial included a heavily pretreated patient population, with a median of four prior lines of therapy, indicating the drug's potential effectiveness in late-line treatment settings [21] Market Data and Key Metrics Changes - Colorectal cancer is a significant global health issue, with approximately 1.9 million new cases diagnosed annually, expected to rise to over 3 million in the coming decades [7][8] - The current five-year survival rate for metastatic colorectal cancer is only 13%, highlighting the urgent need for innovative treatment options [8] Company Strategy and Development Direction - The company aims to position CX-2051 as a new standard of care in late-line colorectal cancer treatment, with plans to expand its use into earlier lines of therapy [36][37] - There is a vision to explore CX-2051's potential in other solid tumors, leveraging the high expression of EpCAM across various cancer types [37][38] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the drug's performance and its potential to transform colorectal cancer treatment, emphasizing the inadequacy of current standard therapies [36][37] - The company plans to generate additional data from ongoing expansions and engage with regulatory authorities to expedite the development process [48][62] Other Important Information - The safety profile of CX-2051 has been favorable, with no dose-limiting toxicities observed to date, and the adverse events reported were manageable and reversible [30][31] - The company is exploring prophylactic strategies to manage gastrointestinal toxicities associated with the treatment [66] Q&A Session Summary Question: What differences are seen between stable disease and responders in terms of baseline characteristics? - Management noted the overall impressive disease control rate and response rate, indicating that they will continue to analyze patient characteristics that may influence outcomes [44][45] Question: What is the current development strategy for pivotal endpoints and moving into earlier lines? - The focus is on generating data from expansion cohorts, with plans to discuss optimal paths for Phase II and potentially Phase III trials with regulatory authorities [48][62] Question: Can you provide details on the management of serious adverse events? - The safety profile is encouraging, and while specific patient details cannot be disclosed, the adverse events reported align with the overall profile [54][55] Question: Are there plans for accelerated development or breakthrough designations? - Discussions with regulatory authorities are anticipated, and the expansion data will be crucial for these conversations [62] Question: Is there evidence of high EpCAM expression in earlier stage patients? - EpCAM is well-established as a CRC target, and its expression is consistent throughout the disease's natural history, supporting its use in earlier treatment lines [71][72] Question: Will higher dosing be considered based on emerging signals? - While the current dose levels are being expanded, the company is cautious about escalating doses without observing dose-limiting toxicities [75][76]

Financial Data and Key Metrics Changes - In Q1 2025, total revenue was $121 million, a decrease of 30% year over year, with subscription services revenue at $108 million, reflecting a 31% decline in subscribers to 3.2 million [19][21] - Adjusted EBITDA for Q1 was $19 million, representing a margin of 16%, while gross margin was 56%, impacted by a one-time charge of $16.2 million due to accelerated depreciation [21][20] - Free cash flow generated in Q1 was approximately $16 million, despite incurring about $8 million in cash outlays related to employee severance from restructurings [21][22] Business Line Data and Key Metrics Changes - The Skills and other revenue segment generated $14 million in Q1, which includes new revenue from content licensing, with two licensing deals executed generating $4 million in Q1 and an expected additional $7 million in Q2 [19][20] - Busuu, the language learning service, saw a 7% year-over-year revenue increase, with the B2B business achieving a 29% year-over-year revenue increase [9] Market Data and Key Metrics Changes - The company is experiencing ongoing industry headwinds, leading to a notable decline in traffic and subscriber acquisitions, which continues to pressure financial performance [24] - The restructuring plan announced is expected to yield non-GAAP expense savings of $45 million to $55 million in 2025 and $100 million to $110 million in 2026 [22][23] Company Strategy and Development Direction - The company is exploring strategic alternatives to maximize shareholder value, including potential acquisition or remaining a standalone public company, with positive early indications from interested parties [7][15] - The focus remains on diversifying revenue through licensing question and answer pairs and expanding institutional contracts, with a goal of reaching 40 institutional pilots by year-end [6][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that macroeconomic trends will continue to exert pressure on the business, with expectations that conditions may worsen before improving [11][12] - The company is taking proactive measures to align costs with business outlook, including further cost reduction plans and restructuring efforts [12][14] Other Important Information - The company repurchased $65 million of its 2026 convertible notes at a discount, enhancing its capital structure [18][22] - The restructuring will impact approximately 22% of the workforce, primarily affecting Chegg Study and Corporate Services, resulting in a 66% reduction in these areas [13][22] Q&A Session Summary Question: Can you provide more details on the licensing deals signed during the quarter? - Management highlighted that they are licensing question and answer pairs from their extensive archive, with current agreements being a small pilot with major tech companies, indicating potential for a larger business model in the future [27][30] Question: What feedback have you received from university partners regarding the pilots? - Management reported positive feedback from universities, with a growing number of pilots and a seat-based license model that aligns with the financial necessity of improving student success rates [31][33]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $21.8 million, down from $24.5 million in Q1 2024, aligning with the higher end of guidance [7][10] - Gross margin decreased to 56% from 60.3% in the previous year [8][14] - Operating loss was $49.7 million compared to a loss of $2.3 million in Q1 2024, primarily due to a goodwill impairment charge of $48 million [8][10] - Adjusted EBITDA was $800,000, down from $1.6 million in Q1 2024 [15] - Cash flow from operations improved to $3 million from $1.4 million in the prior year [16] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 9.4% year-over-year and 5.4% sequentially [11] - European revenue decreased 29% sequentially and 9% year-over-year [12] - APAC revenue increased 6.6% sequentially but was down 17% compared to the prior year [13] Market Data and Key Metrics Changes - The Americas faced a slowdown attributed to budget clarity issues for academic and NIH funding [11] - European sales were impacted by a lack of seasonal bump and lower CRO sales [12] - APAC market showed slight sequential growth but anticipated challenges due to tariff announcements [13] Company Strategy and Development Direction - Focus on expanding adoption of new products while reducing costs, with an expected reduction in operating expenses by an additional $1 million per quarter starting Q2 2025 [25] - New product introductions include the SOHO telemetry devices and VivaMARS system, targeting both academic and industrial customers [19][20] - Emphasis on bioproduction applications and exploring partnerships for CAR T therapy production [21][31] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns over NIH funding and the impact of tariffs on revenue, particularly in China [25][53] - Positive outlook on the adoption of organoid systems due to government policy changes encouraging alternative testing methods [24][34] - Anticipated Q2 revenue guidance is between $18 million to $20 million, with gross margin expected to be in the 55% to 57% range [25] Other Important Information - Goodwill impairment charge of $48 million was recorded due to a decrease in market capitalization [10][29] - Net debt decreased to $30.8 million, reflecting improved cash flow management [16] Q&A Session Summary Question: Can you elaborate on the impairment charge? - Management explained that the impairment was due to a drop in market cap, necessitating a reassessment of goodwill, leading to a non-cash charge of $48 million [29] Question: What about the bioproduction business and CAR T therapy? - Management confirmed that the BTX system is being adopted by a domestic biotech for CAR T therapy production, indicating strong traction in the market [31] Question: How is the MEA product line performing amid NIH funding uncertainties? - Management noted strong interest in the MEA product line, particularly from academic researchers, despite a slowdown in purchasing processes due to NIH staffing changes [34][45] Question: What are the refinancing plans? - Management indicated that refinancing will be more expensive than commercial rates, with terms likely spanning four to five years [46][48]

Financial Data and Key Metrics Changes - The company reported a net loss of $49 million in Q1 2025, with R&D expenses at $44 million and SG&A expenses at nearly $8 million [21][20] - Cash flow from operations consumed $25 million, which is lower than previous quarters due to a temporary working capital gain [21][22] - The company ended Q1 2025 with $288 million in cash, down $15 million from the end of 2024, but total liquidity was $411 million [22] Business Line Data and Key Metrics Changes - The company invested $45 million in program development during the first quarter, focusing on eVTOL, service and support solutions, and urban air traffic management software [20] - The total preorder backlog remains at approximately 2,800 aircraft, valued at around $14 billion, with contracts secured for aftermarket services potentially generating $1.6 billion in revenue [18][19] Market Data and Key Metrics Changes - The company has secured contracts with 14 different customers for its EVE TechCare suite, covering around 1,100 aircraft, which is about 40% of the preorder backlog [19] - The order book includes customers from various sectors, including air mainliners, regional airliners, helicopter operators, ride-sharing platforms, and leasing companies [18] Company Strategy and Development Direction - The company is focused on developing its eVTOL technology and has reached significant milestones, including ground tests and preparations for initial flights [5][6] - The assembly line for the conforming prototypes is set up at Embraer's facility, with plans to start assembly in the second half of 2025 [16][17] - The company aims to create a comprehensive ecosystem for urban air mobility, engaging with partners in infrastructure and energy [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting ambitious targets for prototype assembly and certification campaigns, with initial flights expected in 2026 [20][22] - The company is focused on maintaining a solid cash position and is comfortable with its financial guidance for the year [21][22] Other Important Information - The company is actively engaged with suppliers, with a noticeable increase in activity related to the production of parts for the conforming prototypes [15] - The IronBird simulator is being used to integrate and troubleshoot various systems, which is crucial for the certification campaign [12][13] Q&A Session Summary Question: R&D spending expectations - Management indicated that R&D spending is expected to remain around $44 million per quarter for the rest of the year [26][27] Question: Certification aircraft build timeline - The conforming prototype is on schedule, with the facility ready to receive tooling for assembly [29][30] Question: Services contract backlog details - The $1.6 billion backlog includes battery replacements and repairs but does not account for future upgrades [34][35] Question: Order book and customer engagement - The order book remains stable, with ongoing customer engagement and a focus on developing the first operational city [40][41] Question: Cash consumption guidance - Cash consumption is expected to be closer to the lower end of the $200 million to $250 million range for the year [43][44] Question: Prototypes and cash consumption - Most cash is allocated to R&D, with the focus on development rather than immediate prototype costs [51][52] Question: Service and maintenance business segment - The company is preparing for seamless operation and support for the first aircraft, with training solutions already in development [55][56] Question: Software progress for services - The software side is actively being developed to ensure user-friendliness and operational efficiency [62] Question: Future financing options - The company has multiple funding options available, ensuring sufficient liquidity for upcoming years [65][66]

Ispire Technology (ISPR) Q3 2025 Earnings Call May 12, 2025 08:00 AM ET Speaker0 and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the iSpire Technology Third Quarter twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Philip Carlson from KCSA. ...

Blade Air Mobility (BLDE) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Blade Air Mobility First Quarter twenty twenty five Earnings Release Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, this call is being recorded. I would now like to turn the call over to Matt Snyder, Vice President of Investor Relations ...

Polestar (PSNY) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Pulsar Q1 twenty twenty five Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 1 ...